All News

vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

EGPA: Benralizumab or Mepolizumab

Jack Cush, MD

A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that Benralizumab (BEN) was noninferior to mepolizumab (MEP) for the induction of remission of patients with relapsing or refractory Eosinophilic granulomatosis with polyangiitis (EGPA).

Read Article
RheumNow Podcast square

Immunosuppression Increasing (2.23.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.

Read Article
infusion.biologic.jpg

CD19 CAR T-Cell Therapy in Autoimmune Disease

Jack Cush, MD

The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious.

Read Article
Hand%20squeeze.jpg

ARIAA Trial: Abatacept Delays the Onset of RA

Jack Cush, MD

The ARIAA trial tested the utility of IV abatacept in individuals ACPA+ arthralgia patients with subclinical inflammation and showed abatacept to decrease MRI inflammation, clinical symptoms, and risk of future rheumatoid arthritis (RA) development.

Read Article
RheumNow Podcast square

Curbside Consults (2.16.2024)

Jack Cush, MD

Dr. Jack Cush answers audience clinical case questions sent by email or "ask Cush anything". Cases and questions from:

Read Article
early.ra_.2.jpg

APIPPRA Trial: Abatacept in at-risk rheumatoid arthritis patients

Jack Cush, MD

Abatacept has been studied in seropositive clinically suspect arthralgia patients (at risk for rheumatoid arthritis) and shows the potential to delay or prevent the disease. 

Read Article
Dr. Eder at RNL

Sex Disparities in PsA/SpA

Kathryn H. Dao, M.D.

Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.

Read Article
As of 11/23, FDA has approved 44 biosimilars to 14 different reference products. FDA systematic review on biosimilars found no differences in the risk of death, serious adverse events, or treatment discontinuations between the switch and no-switch arms.https://t.co/yVScZnP559 https://t.co/feswD1gJz9

Links:

Dr. John Cush RheumNow ( View Tweet)
RA BIOBADASER registry study of 1128 patients going on ts/bDMARD found 107 (9.3%) w/ multimorbidity (Charlson Comorbidity index ≥ 3). Multimorbid RA were older, more SJC & signif higher DAS28; ts/bDMARD retention rate equal groups https://t.co/am4Uoccla9 https://t.co/P7Ae2Jal2e

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 2024 EMA meeting approved biosimilar ustekinumab (Pyzchiva) for adult/pediatric psoriasis; psoriatic arthritis; UC/Crohn's. & also approved generic Apremilast Accordfor the treatment of psoriatic arthritis, psoriasis, and Behçet disease https://t.co/Cu9f4qQjgP https://t.co/qmH3ZkfReN

Links:

Dr. John Cush RheumNow ( View Tweet)
Orismilast is a novel oral phosphodiesterase-4 (PDE4) B/D inhibitor studied in phase 2b RCT in 202 moderate-to-severe psoriasis pts vs PBO. At wk 16, Orismilast was better at PASI 75 (40%-49% vs PBO 16.5%; P <.05) and PASI90 (22%-28% vs 8%; P <.05) https://t.co/wSmiO2Hr5W https://t.co/gMiQUfT6EG

Links:

Dr. John Cush RheumNow ( View Tweet)
Oral IL-23 Inhibitor Effective in Psoriasis The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO). https://t.co/NRK8LnM5zp https://t.co/FnWEze976O

Links:

Dr. John Cush RheumNow ( View Tweet)
Tonix is developing a drug, TNX-102 SL, that targets poor sleep quality for fibromyalgia. Phase 3 trial in FM (457 pts) showed TNX-102 SL was better (vs PBO) & improved sleep quality (p=0.0000001 & improved daily pain (p=0.00005) https://t.co/QUNdWyNj2l https://t.co/CzD5TEcgTk

Links:

Dr. John Cush RheumNow ( View Tweet)
Brazilian registry of 1316 RA pts on bDMARDs or JAKi-Added use of antimalarials reduced SAEs & total AEs, & incr survival. 19% were on HCQ, & had signif less SAEs (mIRR: 0.49); AEs (0.68); serious infections (0.53); hepatic AEs (0.21); & mortality (P=.003) https://t.co/bAZ8m3OBo2 https://t.co/SlneyfbJIh

Links:

Dr. John Cush RheumNow ( View Tweet)
Beautiful graphic from Lyu X describing CAR-T development/manufacturing. Dr. @susanshenoi #RWCS24 @RheumNow @RWCSmtg https://t.co/yujfZeBaW7

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Hot off the press! Case report inspired by Dr. George Martin. Topical ruxolitinib efficacy in cutaneous DM. Dr. @susanshenoi #RWCS24 @RWCSmtg @RheumNow https://t.co/uyJdvgJ0ue

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Ixekizumab Safety from 25 RCTs (17 PsO, 4 PsA, 4 axSpA) w/ 9225 pts (22371 PYs use). Long-term safety c/w earlier reports/PI. SAEs in 1204 (13%); 45 deaths); ISRs 5.9-11.6/100PYs; IBD ≤ 0.8/100PY; depression, CVA, Cancer : ≤ 1.6/100PY https://t.co/p7N6ZMVvqh https://t.co/22WYkevhaf

Links:

Dr. John Cush RheumNow ( View Tweet)
"It's hard not to be jealous of the dermatologists." @JointMD discussing the results of JNJ 77242113, po IL-23R, the Frontier 1 trial. #RWCS24 @RWCSmtg @RheumNow https://t.co/1zQ6bu5TM2

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Combo IL-23 and TNFi synergistic benefit in UC in the proof-of-concept VEGA trial. More data to come! #RWCS24 @RWCSmtg @RheumNow https://t.co/FgLTR2PBYJ

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Brazilian registry of 1316 RA pts on bDMARDs or JAKi-Added use of antimalarials reduced SAEs & total AEs, & incr survival. 19% were on HCQ, & had signif less SAEs (mIRR: 0.49); AEs (0.68); serious infections (0.53); hepatic AEs (0.21); & mortality (P=.003) https://t.co/cOeg3KL8Z3 https://t.co/pPRqD7PkXB

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×